Front Desk: 469-391-0070
Margetuximab: Effective HER2-Positive Cancer Treatment Option
Summary of Key Points
Margetuximab is a targeted therapy used to treat certain HER2-positive cancers. It works by binding to cancer cells and helping the immune system destroy them. Margetuximab is typically administered alongside other cancer treatments. Always consult your healthcare provider before starting or adjusting any medication. Our telemedicine providers are available to assist with any questions or concerns you may have.
Names of Medication
US Brand Name: Margenza
Generic Name: Margetuximab
The generic name refers to the active ingredient, while the brand name is assigned by the manufacturer. In this case, Margetuximab is the generic name.
Pharmacologic Category
Monoclonal Antibody
HER2/neu Receptor Antagonist
Margetuximab Dosing Guidelines
Margetuximab is used to treat various HER2-positive cancers, including breast cancer. Dosing schedules may vary depending on the type of cancer being treated. Below are typical dosing guidelines for adults:
HER2-Positive Breast Cancer
Dosage: 15 mg/kg administered intravenously (IV) every 3 weeks in combination with chemotherapy.
Length of Treatment: Continue until disease progression or unacceptable toxicity occurs.
HER2-Positive Gastric Cancer
Dosage: 15 mg/kg administered intravenously (IV) every 3 weeks in combination with chemotherapy.
Length of Treatment: Continue until disease progression or unacceptable toxicity occurs.
HER2-Positive Esophageal Cancer
Dosage: 15 mg/kg administered intravenously (IV) every 3 weeks in combination with chemotherapy.
Length of Treatment: Continue until disease progression or unacceptable toxicity occurs.
Other HER2-Positive Cancers (Colorectal, Head and Neck, Lung, Pancreatic, Ovarian, Uterine)
Dosage: 15 mg/kg administered intravenously (IV) every 3 weeks in combination with chemotherapy.
Length of Treatment: Continue until disease progression or unacceptable toxicity occurs.
Always consult your doctor before making any changes to your dose. If you have questions about your treatment plan, our telemedicine providers are available to assist you.
Dosage Forms and Strengths
Intravenous solution: 250 mg/10 mL (25 mg/mL)
Administration Instructions for Margetuximab
Margetuximab is administered as an intravenous (IV) infusion by a healthcare professional. The first dose typically takes about 2 hours, with subsequent doses potentially shortened if well tolerated. It is essential to attend all scheduled infusion appointments. Your healthcare provider will monitor you for any side effects during and after the infusion. If you experience any unusual symptoms, notify your healthcare provider immediately.
Margetuximab Side Effects and Adverse Reactions
Like all medications, Margetuximab can cause side effects. Some are common, while others are rare but more serious. It is important to discuss any side effects with your healthcare provider. Below are some potential side effects of Margetuximab:
- Fatigue: Feeling unusually tired is common. Rest and staying hydrated may help alleviate this symptom.
- Nausea: You may experience nausea. Your doctor can prescribe medications to help manage this side effect.
- Infusion-related reactions: Fever, chills, or rash may occur during or after the infusion. These reactions are usually mild but should be reported to your healthcare provider.
- Diarrhea: Loose stools are a common side effect. Staying hydrated and following a bland diet may help manage this.
- Decreased white blood cell count (Neutropenia): This can increase your risk of infections. Your healthcare provider will monitor your blood counts regularly.
- Heart problems: Margetuximab can affect heart function. Your doctor may perform tests to monitor your heart health during treatment.
If you experience severe side effects, such as difficulty breathing, chest pain, or signs of infection, contact your healthcare provider immediately. Our telemedicine service is available to provide support and guidance if you have concerns about your treatment.
Contraindications for Margetuximab Treatment
A contraindication is a specific condition where a treatment should not be used due to potential harm. For Margetuximab, certain conditions make its use inadvisable due to associated risks.
- Severe allergic reactions to Margetuximab or similar medications: If you have had a serious allergic reaction to Margetuximab or other monoclonal antibodies, you should not take this medication. Allergic reactions can include difficulty breathing, swelling, or severe rash, which can be life-threatening.
- Active or untreated infections: Margetuximab can weaken your immune system, making it harder to fight infections. If you have an active infection, taking Margetuximab could worsen your condition.
- Heart conditions: Margetuximab may affect heart function, especially in patients with pre-existing heart conditions. If you have a history of heart failure or other heart diseases, your healthcare provider may recommend alternative treatments.
Drug-to-Drug Interactions with Margetuximab
It is important to inform your healthcare provider about all medications you are currently taking, as Margetuximab can interact with other drugs. Some medications that may interact with Margetuximab include:
- Trastuzumab (Herceptin): Combining Margetuximab with Trastuzumab may increase the risk of heart problems, as both drugs target the HER2 protein and can affect heart function.
- Anthracyclines (Doxorubicin, Epirubicin): These chemotherapy drugs can increase the risk of heart damage when used with Margetuximab.
- Immunosuppressants (Tacrolimus, Cyclosporine): These medications suppress the immune system and may increase the risk of infections when taken with Margetuximab.
Margetuximab in Pregnancy
Is it safe to take Margetuximab when pregnant?
Margetuximab is generally not recommended during pregnancy unless absolutely necessary. This monoclonal antibody therapy may pose risks to an unborn baby by potentially interfering with fetal development. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks and benefits of continuing Margetuximab with your healthcare provider. Should you become pregnant while undergoing treatment, contact your healthcare provider immediately to discuss your options.
Margetuximab while Breastfeeding
Is it safe to take Margetuximab while breastfeeding?
It is currently unclear whether Margetuximab passes into breast milk. Due to the potential for serious side effects in a breastfeeding infant, it is generally advised to avoid breastfeeding while receiving Margetuximab. Be sure to discuss your breastfeeding options with your healthcare provider before starting treatment, as they may recommend alternatives during this time.
Estimated Cost of Margetuximab Treatment
The cost of Margetuximab can vary depending on your location and pharmacy. Without insurance, a 30-day supply using a GoodRX coupon is estimated to range between $9,000 and $12,000. For the most accurate pricing, check with your pharmacy, and explore financial assistance programs if needed.
Possible Alternatives to Margetuximab
If Margetuximab is not suitable for you, other treatment options may be available. Always consult your healthcare provider before making any changes to your treatment plan. You can also schedule a telemedicine appointment with one of our providers to explore your options.
Breast Cancer
Alternatives may include Trastuzumab (Herceptin), Pertuzumab (Perjeta), or chemotherapy options such as Paclitaxel (Taxol). Hormonal therapies like Tamoxifen may also be considered for certain types of breast cancer.
Gastric Cancer
Other treatment options may include Ramucirumab (Cyramza), chemotherapy, or radiation therapy. Additionally, lifestyle changes, such as maintaining a healthy diet and avoiding smoking, may help manage symptoms.
Esophageal Cancer
Alternatives may include surgery, radiation therapy, or chemotherapy with drugs like Cisplatin or 5-Fluorouracil (5-FU). Dietary changes, discussed with a nutritionist, may also help manage symptoms.
HER2-Positive Cancer
Trastuzumab (Herceptin) and Pertuzumab (Perjeta) are commonly used alternatives. Targeted therapies such as Lapatinib (Tykerb) may also be considered.
Colorectal Cancer
Treatment options may include chemotherapy with drugs like Oxaliplatin or Capecitabine (Xeloda), as well as targeted therapies such as Bevacizumab (Avastin).
Head and Neck Cancer
Alternatives may include surgery, radiation therapy, and chemotherapy with drugs like Cisplatin or Cetuximab (Erbitux).
Lung Cancer
Other treatment options may include Pembrolizumab (Keytruda), chemotherapy, or targeted therapies like Osimertinib (Tagrisso).
Pancreatic Cancer
Alternatives may include chemotherapy with drugs like Gemcitabine or FOLFIRINOX, as well as surgery or radiation therapy.
Ovarian Cancer
Treatment options may include chemotherapy with drugs like Carboplatin or Paclitaxel, as well as targeted therapies such as Bevacizumab (Avastin).
Uterine Cancer
Alternatives may include surgery, radiation therapy, and hormonal treatments such as Medroxyprogesterone (Provera).
Recent Updates on Margetuximab Research
Recent studies suggest that Margetuximab may benefit patients with HER2-positive breast cancer who have previously been treated with other HER2-targeted therapies. Ongoing research is also exploring the use of Margetuximab in combination with other treatments, such as immunotherapies, to improve outcomes for patients with various HER2-positive cancers.
The SOPHIA clinical trial demonstrated that Margetuximab, when combined with chemotherapy, significantly improved progression-free survival compared to Trastuzumab in patients with HER2-positive metastatic breast cancer. Researchers are also investigating Margetuximab’s effectiveness in other HER2-positive cancers, including gastric and esophageal cancers.
As research continues, staying informed about new developments is essential. Discuss any new findings with your healthcare provider to determine if they may impact your treatment plan. If you have questions or concerns, our telemedicine providers are available to help you navigate your treatment options.
